Bespak ready to break with the past, maintains growth plans despite Exubera hitch
This article was originally published in Clinica
Executive Summary
A good financial performance in the year 2006-07 for UK drug delivery and anaesthesia device specialist Bespak was tempered marginally by its board's comments that the current year will be "broadly flat". This, it said, would be as a result of declining sales of valves for ozone-depleting CFC formulations in the US and a fall in production volumes of the Exubera insulin inhaler device, following slower-than-expected uptake of the device.
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.